Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America

Table 1

Nomenclature of SARS-CoV-2 variants and noticeable pathological characteristics.

WHO label	Pango lineages	GISAID	Nextstrain	First discovered	Increased
					Infection	Severity/lethality	Vaccine resist
Currently designated variants of concern
Alpha	B.1.1.7	GRY	20I (V1)	UK, Sep-2020	Yes; >20%	Yes; >50%
Beta	B.1.351	GH/501Y.V2	20H (V2)	South Africa, May-2020	Yes; >50%		Reduced
	B.1.351.2−
Gamma	P.1	GR/501Y.V3	20J (V3)	Brazil, Nov-2020	Yes; >50%	Possibly
	P.1.1–2					Increased
Delta	B.1.617.2	G/478K.V1	21A	India, Oct-2020	Yes; >60%	Yes; >50%	Reduced
	AY.1/2
Omicron	B.1.1.529	GR/484A	21K	Multiple countries, Nov-2021	UI∼>60%	UI	UI
Currently designated variants of interest
Lambda	C.37	GR/452Q.V1	21G	Peru, Dec-2020	UI	UI	UI
Mu	B.1.621	GH	21H	Colombia, Jan-2021	UI	UI	UI
Currently designated alerts for further monitoring
Epsilon	B.1.427	GH/452R.V1	21C	United States, Mar-2020	Yes; >15%		Possibly
	B.1.429						Reduced
Zeta	P.2	GR/484K.V2	20B	Brazil, Apr-2020	UI
Theta	P.3∗	GR/1092K.V1	21E	Philippines, Jan-2021	UI
	R.1	GR	—	Multiple countries, Jan-2021	UI
	R.2
	B.1.466.2	GH	—	Indonesia, Nov-2020	UI
	AV.1	GR	—	UK, Mar-2021	UI
	B.1.1.318	GR	20B	Multiple countries, Jan-2021	UI
	B.1.1.519	GR	20B	Multiple countries, Nov-2020	UI
	AT.1	GR	—	Russia, Jan-2021	UI
	B.1.214.2	G	—	Multiple countries, Nov-2020	UI

UI: under investigation. Our own source. Data from OMS, CDC, ECDC, and Outbreak.info.